Table 1. Characteristics of eligible studies included in this study.
| Reference | Country (ethnicity) | Cases/ Controls | Genotyping method | Source of controls | Type of controls | Type of cases | Polymorphisms of VEGF-A gene |
|---|---|---|---|---|---|---|---|
| [23] |
China (Asian) |
159/140 |
MassArray |
Hospital |
Age, gender, and ethnicity matched without AMD |
Neovascular AMD |
rs833061, rs1413711, rs2010963, rs3025039 |
| [24] |
Brazil (mixed) |
160/140 |
TaqMan |
Hospital |
Age and gender matched without AMD, |
Exudative and nonexudative AMD |
rs1413711 |
| [25] |
Finland (Caucasian) |
162/85 |
TaqMan |
Hospital |
Age matched without AMD |
Exudative AMD |
rs699947, rs2146323, rs3025033 |
| [26] |
Italy (Caucasian) |
226/248 |
PCR-SBE |
Hospital |
Gender and ethnicity matched without detectable drusen |
Neovascular and nonneovascular AMD |
rs833068, rs833069, rs3024994, rs3025007, rs3025039 |
| [15] |
Poland (Caucasian) |
265/136 |
Allele-specific PCR and PCR-RFLP |
Hospital |
Age and gender matched without AMD |
Atrophic and neovascular AMD |
rs833061, rs2010963 |
| [27] |
USA (Caucasian) |
211/187 |
Hospital |
Without AMD |
Atrophic and neovascular AMD |
rs833070 |
|
| [16] |
China (Asian) |
190/180 |
PCR-RFLP |
Hospital |
Age and gender matched without any type of drusen, geographic atrophy, CNV, or other retinal disorder in either eye |
Atrophic and neovascular AMD |
rs699947, rs833061, rs1413711, rs2010963, rs3025039 |
| [28] |
Australia (Caucasian) |
577/173 |
MassArray |
Population |
Ethnicity and residence matched without AMD |
Early, atrophic, and neovascular AMD |
rs10434, rs25648, rs833061, rs2146323, rs3024997, rs3025030, rs3025035 |
| [13] | UK (Caucasian) | 45/94 | PCR | Hospital | Age matched healthy | Neovascular AMD | rs735286, rs1413711, rs2146323, rs3025021, rs3025024 |
PCR polymerase chain reaction; SBE single base extension; RFLP restriction fragment length polymorphism.